#South Korea #Cambridge #HoneyNaps #SOMNUM #ICT Unicorn

HoneyNaps Recognized as a Leading SleepTech Innovator in Korea's 2026 Global ICT Unicorn Program

HoneyNaps Selected for Korea's 2026 Global ICT Unicorn Program

HoneyNaps, a pioneer in AI-driven sleep healthcare solutions, has recently achieved a noteworthy milestone by being selected for the 2026 Global ICT Unicorn Program organized by the Ministry of Science and ICT and the National IT Industry Promotion Agency (NIPA) in Korea. This selection is particularly significant as HoneyNaps becomes the first company in the SleepTech sector to be recognized by this government-led initiative, which aims to foster high-growth technology companies with exceptional global expansion potential.

The Global ICT Unicorn Program is designed to support innovative companies that display strong characteristics for growth and potential for international reach. Participating companies receive extensive support, which includes opportunities for international market expansion, access to investment networks, policy financing, and a platform for global networking. In 2026, a total of 15 cutting-edge companies in various ICT sectors, including artificial intelligence and healthcare, were chosen to participate, underscoring HoneyNaps’ impressive technological capabilities and business potential.

Central to HoneyNaps’ growth strategy is its FDA-cleared AI sleep disorder diagnostic solution, SOMNUM. This innovative product not only provides an advanced assessment of sleep-related health issues but is also integral to the company's ongoing efforts to build a comprehensive AI-based sleep healthcare ecosystem. Key components of this ecosystem include:

- SOMNUM Pro: An AI-powered on-premise scoring software tailored for hospitals and sleep clinics, enhancing diagnostic accuracy.
- SOMNUM Cloud: A web-centric platform which facilitates large-scale analysis and interpretation of sleep data, making it easier for healthcare providers to offer precise and timely care.
- SOMNUM Clinical Service: A dedicated service for clinical trial analysis and operational support targeted at pharmaceutical companies and research institutions.

These innovations form the backbone of HoneyNaps’ mission to deliver high-quality sleep analysis and operational efficiency within healthcare settings.

In addition to its recent selection for the ICT Unicorn Program, HoneyNaps has also been endorsed by the 2026 Korea BioHealth Value-up Innovation Program (K-VIP), organized by the Korea Health Industry Development Institute (KHIDI). This recognition has furthered HoneyNaps’ expansion in the U.S. by establishing a presence at the Cambridge Innovation Center located in Kendall Square, Boston.

The Boston site serves as a strategic base from which HoneyNaps is working to strengthen collaborations with top U.S. hospitals and sleep centers. The company is actively pursuing joint research and clinical partnerships with various pharmaceutical and medical device firms. Furthermore, HoneyNaps is developing a Korean sleep foundation model utilizing multimodal polysomnography (PSG) data. This model aims to extend the application of AI technologies to not just sleep disorders, but also cardiovascular and neurological diseases, enhancing clinical decision-making processes.

Sean Ha, the President of HoneyNaps USA, expressed optimism regarding the dual achievements of being selected for the Global ICT Unicorn Program and expanding into Kendall Square. He remarked, “These milestones provide robust momentum for our international business growth. By leveraging our FDA-approved technology, strategic U.S. clinical network, and substantial government support, we are poised to represent Korea as a leading AI sleep healthcare company on the global stage.”

HoneyNaps is based in South Korea and focuses on pioneering digital health solutions through AI-driven diagnostics for sleep disorders. The company's aim is to improve the accessibility, efficiency, and clinical accuracy of sleep medicine using cutting-edge technology and scalable healthcare platforms.